MAXCYTE, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 377 GBX | +4.14% |
|
+0.53% | +6.95% |
| 05-22 | MaxCyte inks deal with Legend Biotech for tech supply | AN |
| 05-22 | MaxCyte Signs License Deal With Legend Biotech for Cell Therapy Program | MT |
Presenter SpeechDouglas Doerfler (Executives)[Audio Gap]
And than...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
MaxCyte, Inc. is a commercial cell engineering company. The Company is focused on providing enabling platform technologies to advance the discovery, development and commercialization of cell therapeutics, including cell and gene therapies, and to support cell-based research and development. It has developed and commercialized its proprietary Flow Electroporation technology, which is used by biopharmaceutical companies in the complex engineering of a variety of cells. Its ExPERT platform is based on its Flow Electroporation technology, which has been designed to address this rapidly expanding cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of cell-based medicines. The ExPERT family of products includes four instruments, which are known as the ATx, STx, GTx and VLx, as well as a portfolio of proprietary related disposables and consumables.
Calendar
11/06/2024
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
4.626
USD
Average target price
6.94
USD
Spread / Average Target
+50.02%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +6.95% | 484M | |
| +7.87% | 219B | |
| +11.83% | 192B | |
| +18.87% | 142B | |
| +30.03% | 111B | |
| +1.79% | 65.32B | |
| +14.15% | 52.45B | |
| +2.68% | 49.8B | |
| +6.60% | 43.43B | |
| +1.85% | 35.95B |
- Stock Market
- Equities
- MXCT Stock
- News MaxCyte, Inc.
- Transcript : MaxCyte, Inc. Presents at Bank of America 2022 Healthcare Conference, May-11-2022 04
